Snake-shaped Arm Technology Accelerates Multi-Disciplinary Clinical Dominance

Date: May 6, 2025, The Surgerii^® Single-Port Robotic System has received approval from China’s National Medical Products Administration (NMPA) for expanded indications (Registration No.: GuoXieZhuZhun 20233010833). Its scope now covers “urology, gynecology, general surgery, and thoracic surgery (lung procedures) under physician-controlled master-slave manipulation for minimally invasive surgical operations.” 

With this milestone, Surgerii^® Robot becomes China’s first and only single-port surgical robot approved for four major surgical specialties, solidifying China’s leadership in next-generation minimally invasive technologies on the global stage.

Since its initial approval in 2023, Surgerii^® Robot has achieved widespread commercialization across top-tier hospitals in China, with clinical collaborations spanning over 50 institutions. Its applications extend across urology, gynecology, general surgery, thoracic surgery, and pediatric surgery, driving innovative surgical practices and enabling large-scale adoption of single-port robotic procedures—even surpassing adoption rates in Europe. Notably, Surgerii^® recently made history by enabling China’s first transcontinental remote lung cancer surgery between China and Romania, showcasing the export of China’s cutting-edge medical expertise to developed markets. With the newly approved general and thoracic surgery indications, Surgerii^® now addresses critical diseases such as gastric and lung cancers, offering patients safer, more precise, and minimally invasive options. The system is also expanding into cardiac, head and neck, and oral-maxillofacial surgery, further advancing multi-disciplinary innovation.

Surgerii^® Robot, with its cutting-edge technology and clinical adaptability, is continuously transcending the limitations of traditional surgical approaches, reshaping the landscape of surgical procedures, and driving the widespread adoption and application of robotic-assisted surgery across diverse medical specialties.

From Abdomen to Thorax: Snake-shaped Arm Redefines Surgical Frontiers

Leveraging its globally pioneering Snake-shaped Arm technology, Surgerii^® Robot has collaborated with Ruijin Hospital (affiliated with Shanghai Jiao Tong University School of Medicine), Shandong Provincial Hospital, and Guangzhou Medical University’s First Affiliated Hospital to complete rigorous clinical trials and high-complexity surgical validations:

General Surgery

In trials led by Ruijin Hospital and Shandong Provincial Hospital, Surgerii^®’s multi-degree-of-freedom Snake-shaped Arms demonstrated exceptional flexibility and load capacity, overcoming traditional single-port limitations in anatomical access and maneuverability. The robot has successfully performed complex procedures, including distal gastrectomy (Billroth I anastomosis), single-port robotic total gastrectomy (Overlap esophagojejunostomy), and single-port robotic total colectomy.

 In 2023, Prof. Ren Zhao’s team at Ruijin Hospital published groundbreaking research in the International Journal of Surgery (IF: 15.3), marking global recognition of Chinese single-port robotic innovation. Similarly, Prof. Leping Li and Prof. Liang Shang’s team at Shandong Provincial Hospital reported the world’s first pure single-port robotic total gastrectomy in the Chinese Medical Journal, advancing the treatment of advanced gastric cancers.

Thoracic Surgery

In late 2023, Prof. Jianxing He’s team at Guangzhou Medical University’s First Affiliated Hospital pioneered China’s first single-port robotic thoracic surgery—a right upper lobectomy with mediastinal lymph node dissection. By 2024, the team completed Surgerii^®’s thoracic surgery trials, resolving long-standing challenges in single-port thoracoscopy. Traditional multi-port robots require 3-5 incisions, while single-port thoracoscopy faces “chopstick effect” limitations. Surgerii^®’s flat triple-channel trocar enables instruments and endoscopes to enter through a single 3-4 cm intercostal incision, while its Snake-shaped Arms provide unparalleled dexterity for intricate maneuvers in confined thoracic spaces. This breakthrough balances minimal invasiveness with surgical efficiency, redefining lung cancer treatment.

Global Expansion | Surgerii^® Accelerates China’s Homegrown Tech to the World

Surgerii^® Robot embodies the vision of “Boundless Access·Infinite Possibilities,” standardizing single-port minimally invasive surgery for global adoption.

From remote island-based military scenarios to transcontinental “rotating”remote surgeries, Surgerii^® continues to shatter boundaries. In April 2025, it achieved the world’s first transcontinental thoracic remote surgery: a team in Suzhou, China, successfully performed a lung cancer resection on a patient 8,000 km away in Europe. Esteemed thoracic surgeon Diego González Rivas praised, “Surgerii^® Robot’s technological sophistication rivals or surpasses global leaders.” 

By integrating its proprietary SURG-Box remote system with 5G, Surgerii^® is building a low-latency, high-stability surgical network to connect experts across regions and continents.

Defining the Future | Surgerii^® Leads the Era of Ultra-Minimally Invasive Surgery

Rooted in its Snake-shaped Arm technology and powered by the S+Suite Platform—including the SRS Remote Surgery System, SE Hybrid Energy Device, and S-Center Translational Hub—Surgerii^® is rewriting surgical paradigms, establishing “Chinese Innovation, Global Standards.” Here, sub-millimeter precision meets human-centric care.

Here, Chinese ingenuity transitions from follower to pioneer.

Surgerii^® Robot, with Eastern wisdom, transcends borders to unlock a new era for global health.